Isoquercetin in Sickle Cell Anemia
Palabras clave
Abstracto
Descripción
This is a single-arm phase 2 study in adults with Sickle Cell Disease (SCD) to assess the effect of oral isoquercetin on biomarkers of endothelial and platelet activation, inflammation and ongoing blood coagulation.
- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
- The names of the study drug involved in this study are/is: Isoquercetin
- Participants will receive study treatment for 1 year and will be followed for 30 days after the last dose.
- This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
- The U.S. Food and Drug Administration (FDA) has not approved isoquercetin as a treatment for any disease.
fechas
| Verificado por última vez: | 06/30/2020 |
| Primero enviado: | 07/05/2020 |
| Inscripción estimada enviada: | 07/12/2020 |
| Publicado por primera vez: | 07/16/2020 |
| Última actualización enviada: | 07/12/2020 |
| Última actualización publicada: | 07/16/2020 |
| Fecha de inicio real del estudio: | 08/31/2020 |
| Fecha estimada de finalización primaria: | 12/30/2022 |
| Fecha estimada de finalización del estudio: | 12/30/2024 |
Condición o enfermedad
Intervención / tratamiento
Drug: ISOQUERCETIN
Fase
Grupos de brazos
| Brazo | Intervención / tratamiento |
|---|---|
| Experimental: ISOQUERCETIN The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits
- ISOQUERCETIN: Oral Study Drug, 1 time per day, per predetermined dosed per 28 treatment cycle.
This will continue for up to 337 days. | Drug: ISOQUERCETIN Oral, 1 time per day, per predetermined dosed per 28 treatment cycle. |
Criterio de elegibilidad
| Edades elegibles para estudiar | 18 Years A 18 Years |
| Sexos elegibles para estudiar | All |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: - Eligible subjects require an established diagnosis of sickle cell disease/homozygous hemoglobin S (SCD-SS) or sickle cell disease hemoglobin β0-thalassemia (SCD-Sβ0-thal). - Patients on other therapy including hydroxyurea will be included. - Age 18-50 years. - Participants must have preserved organ and marrow function as defined below: - leukocytes ≥2,000/mcL - platelets ≥75,000/mcL - AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal - Estimated creatinine clearance ≥45 mL/min/1.73 m2 for participants with creatinine levels above institutional normal. - Subjects with no evidence of worsening over the last 4 weeks (e.g. any acute complication of SCD including but not limited to VOC, acute chest syndrome and stroke, that required unscheduled medical attention or intervention) as determined by the investigator will be included. - Patients on anticoagulation therapy will be excluded. - The effects of isoquercetin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of isoquercetin administration. - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Please ensure exclusion criteria are clearly worded to describe participants who will not be eligible. - Participants may not be concurrently receiving any other study agents. - Subjects with no evidence of worsening over the last 1 month (e.g. any acute complication of SCD including but not limited to VOC, acute chest syndrome and stroke, that required unscheduled medical attention or intervention) as determined by the investigator will be included. - Familial bleeding diathesis. - Known diagnosis of disseminated intravascular coagulation. - Currently receiving anticoagulant therapy. - Currently using daily use of aspirin (>81mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) - History of allergic reactions attributed to compounds of similar chemical or biologic composition to isoquercetin. - Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness/social situations that would limit study compliance. - Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with isoquercetin. These potential risks may also apply to other agents used in this study. |
Salir
Medidas de resultado primarias
1. Change in sP Selectin levels with isoquercetin [baseline to 28 Days]
Medidas de resultado secundarias
1. Platelet dependent thrombin generation (coagulation) [baseline to 1 year]
2. sE-selectin (adhesion)-Biomarker [baseline to 1 year]
3. C-reactive protein CRP [baseline to 1 year]
4. Number of Participants With Treatment-Related Adverse Events [start of study treatment up to 13 months]
